uniQure (NASDAQ:QURE) reported updated Phase I/II data for its investigational Huntington’s disease gene therapy, ifezuntirgene inilparvovec, or AMT-130, including 36-month results from all high-dose patients and 48-month results from the first 12 high-dose patients to reach that milestone.
The com
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure (NASDAQ:QURE) shares
uniQure (NASDAQ:QURE) said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease, and remains on track to submit a biologics license application in the third quarter of 2026.
Chief
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s. Previous close: $26.99. An 81% gain, overnight. Read that last number again. This stock nearly doubled in a single session. Now, I…
Mizuho said that Dr. Vinay Prasad’s exit just days after a highly public dispute with uniQure appeared to signal an administration-level desire to restore greater regulatory flexibility in rare disease development.
Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.
